Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 11Stomach Neoplasms 6Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Salivary Gland Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1

Interventions

Oxaliplatin 9Capecitabine 9pembrolizumab 7Paclitaxel 7Fluorouracil 7Leucovorin 6Cisplatin 6zolbetuximab 5Gemcitabine 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Pemetrexed 3Docetaxel 3Carboplatin 3130-nm albumin-bound paclitaxel 3fludarabine 2darolutamide 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Nivolumab 2Irinotecan 2Cyclophosphamide 2Androgen Antagonists 2Albumin-Bound Paclitaxel 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × trastuzumab deruxtecan × 90 days × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡